MX2015004884A - Uso de ivermectina y derivados de la misma. - Google Patents
Uso de ivermectina y derivados de la misma.Info
- Publication number
- MX2015004884A MX2015004884A MX2015004884A MX2015004884A MX2015004884A MX 2015004884 A MX2015004884 A MX 2015004884A MX 2015004884 A MX2015004884 A MX 2015004884A MX 2015004884 A MX2015004884 A MX 2015004884A MX 2015004884 A MX2015004884 A MX 2015004884A
- Authority
- MX
- Mexico
- Prior art keywords
- ivermectin
- derivatives
- doramectin
- avermectin
- abamectin
- Prior art date
Links
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 title abstract 3
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 title abstract 3
- 229960002418 ivermectin Drugs 0.000 title abstract 3
- 239000005660 Abamectin Substances 0.000 abstract 4
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 abstract 2
- 229950008167 abamectin Drugs 0.000 abstract 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 abstract 2
- 229960003997 doramectin Drugs 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003096 antiparasitic agent Substances 0.000 abstract 1
- 229940125687 antiparasitic agent Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 208000001130 gallstones Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Abstract
La presente invención se refiere al nuevo uso de agentes antiparasitarios, tal como ivermectina, abamectina/avermectina, doramectina y demás, y al método de diseño de los derivados para el nuevo uso. Estos compuestos, incluyendo los macrólidos abamectina/avermectina, ivermectina, doramectina y derivados de los mismo, se pueden usar en la elaboración de un medicamento para el uso en el tratamiento de enfermedades metabólicas relacionas, en un mamífero, tal como hiperglicemia, resistencia a insulina, hipertrigliceridemia, hipercolesterolemia, diabetes, obesidad, etc, y enfermedades mediadas por el receptor Famesoide X, tal como colestasis, cálculo biliar, enfermedad de hígado graso no de origen alcohólico, aterosclerosis, inflamación, cáncer, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210403320.2A CN102872066B (zh) | 2012-10-19 | 2012-10-19 | 伊维菌素及其衍生物的用途 |
| PCT/CN2013/077796 WO2014059797A1 (zh) | 2012-10-19 | 2013-06-24 | 伊维菌素及其衍生物的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015004884A true MX2015004884A (es) | 2015-10-05 |
Family
ID=47473737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004884A MX2015004884A (es) | 2012-10-19 | 2013-06-24 | Uso de ivermectina y derivados de la misma. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10052340B2 (es) |
| EP (1) | EP2918274A1 (es) |
| JP (1) | JP2015534954A (es) |
| KR (1) | KR20150081433A (es) |
| CN (3) | CN102872066B (es) |
| AU (1) | AU2013330877A1 (es) |
| BR (1) | BR112015008908A2 (es) |
| CA (1) | CA2889047A1 (es) |
| MX (1) | MX2015004884A (es) |
| RU (1) | RU2015118579A (es) |
| WO (1) | WO2014059797A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872066B (zh) | 2012-10-19 | 2014-07-02 | 厦门大学 | 伊维菌素及其衍生物的用途 |
| TW201615194A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 氨苯蝶啶藥物應用於癌症治療 |
| FR3042412A1 (fr) * | 2015-10-14 | 2017-04-21 | Biotopic Pharmaceuticals | Formulation pharmaceutique stabilisee et prete a l'emploi d'ivermectine dans le traitement des parasitoses humaines et animales |
| CN105477636B (zh) * | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| CN106237332A (zh) * | 2016-08-11 | 2016-12-21 | 河南大学 | 核受体fxr在肝癌干细胞靶向治疗中的应用 |
| CN108707173A (zh) * | 2017-04-06 | 2018-10-26 | 合帕吉恩治疗公司 | 作为fxr调节剂的阿维菌素衍生物 |
| JP2020526537A (ja) * | 2017-07-14 | 2020-08-31 | ユニバーシティ オブ マサチューセッツ | 炎症を処置するための方法および組成物 |
| CN108524533A (zh) * | 2018-06-05 | 2018-09-14 | 中国科学院动物研究所 | 一种化合物用作抗肿瘤药物增效剂和逆转剂 |
| CN111789862A (zh) * | 2020-08-22 | 2020-10-20 | 东北农业大学 | 多拉菌素在治疗胶质瘤中的应用 |
| CN112057461A (zh) * | 2020-09-15 | 2020-12-11 | 东北农业大学 | 多拉菌素在治疗食管癌中的应用 |
| US11291679B1 (en) * | 2021-03-22 | 2022-04-05 | Mountain Valley Md Inc. | Injectable, infusable, instillable ivermectin adjuvant for cancer therapies |
| CN120037250A (zh) * | 2025-04-07 | 2025-05-27 | 江苏知原药业股份有限公司 | 一种伊维菌素外用药物组合物、制备方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4199569A (en) * | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
| ES8800986A1 (es) * | 1985-07-27 | 1987-12-01 | Pfizer | Un procedimiento para la produccion de un nuevo derivado de avermectina |
| US5248669A (en) * | 1991-12-17 | 1993-09-28 | Samir Amer | Inhibition of anoxia or hypoxia-induced, endothelium-mediated vasospasm with avermectins |
| WO2004006906A2 (en) * | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| FR2854074B1 (fr) | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
| AU2004231323C1 (en) | 2003-04-24 | 2016-11-03 | Galderma Holding SA | Topical formulation of ivermectin for the treatment of dermatological conditions |
| FR2867684B1 (fr) | 2004-03-18 | 2006-05-05 | Galderma Sa | Gel creme contenant de l'ivermectine |
| GB0618403D0 (en) * | 2006-09-19 | 2006-11-01 | Leuven K U Res & Dev | Treatment of amyotrophic lateral sclerosis |
| CA2745457A1 (fr) * | 2008-12-23 | 2010-07-01 | Galderma S.A. | Composition pharmaceutique topique comprenant un principe actif sensible a l'eau |
| WO2011011632A1 (en) * | 2009-07-22 | 2011-01-27 | Tufts University | Methods and compositions for modulating membrane potential to influence cell behavior |
| CN102872066B (zh) * | 2012-10-19 | 2014-07-02 | 厦门大学 | 伊维菌素及其衍生物的用途 |
-
2012
- 2012-10-19 CN CN201210403320.2A patent/CN102872066B/zh active Active
- 2012-10-19 CN CN201310324876.7A patent/CN103356687B/zh active Active
-
2013
- 2013-06-24 WO PCT/CN2013/077796 patent/WO2014059797A1/zh not_active Ceased
- 2013-06-24 EP EP13846857.4A patent/EP2918274A1/en not_active Withdrawn
- 2013-06-24 MX MX2015004884A patent/MX2015004884A/es unknown
- 2013-06-24 AU AU2013330877A patent/AU2013330877A1/en not_active Abandoned
- 2013-06-24 US US14/436,836 patent/US10052340B2/en active Active
- 2013-06-24 CA CA2889047A patent/CA2889047A1/en not_active Abandoned
- 2013-06-24 JP JP2015537115A patent/JP2015534954A/ja active Pending
- 2013-06-24 BR BR112015008908A patent/BR112015008908A2/pt not_active IP Right Cessation
- 2013-06-24 RU RU2015118579A patent/RU2015118579A/ru not_active Application Discontinuation
- 2013-06-24 CN CN201380054801.XA patent/CN105473148A/zh active Pending
- 2013-06-24 KR KR1020157012948A patent/KR20150081433A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014059797A1 (zh) | 2014-04-24 |
| CN103356687B (zh) | 2016-06-01 |
| EP2918274A1 (en) | 2015-09-16 |
| CN102872066A (zh) | 2013-01-16 |
| JP2015534954A (ja) | 2015-12-07 |
| RU2015118579A (ru) | 2016-12-10 |
| CN105473148A (zh) | 2016-04-06 |
| BR112015008908A2 (pt) | 2017-07-04 |
| AU2013330877A1 (en) | 2015-05-21 |
| US20150306123A1 (en) | 2015-10-29 |
| CA2889047A1 (en) | 2014-04-24 |
| CN103356687A (zh) | 2013-10-23 |
| CN102872066B (zh) | 2014-07-02 |
| US10052340B2 (en) | 2018-08-21 |
| KR20150081433A (ko) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015004884A (es) | Uso de ivermectina y derivados de la misma. | |
| MX2022009595A (es) | Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas. | |
| EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| ZA201505849B (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| ECSP12011716A (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| BR112015010360A8 (pt) | antagonistas de il-6 e utilização dos mesmos. | |
| ZA201208069B (en) | Methods and devices for drug delivery to ocular tissue using microneedle | |
| BR112014018378A8 (pt) | Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| PL2643004T3 (pl) | Kompozycja oligosacharydów do leczenia chorób skóry | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| DOP2010000012A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| BRPI0911273B8 (pt) | composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação | |
| HK1200714A1 (en) | Fgfr-binder-active agent conjugates | |
| BRPI0810081A2 (pt) | Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial | |
| BR112012003286A2 (pt) | formulações farmacêuticas contra o mau uso dos medicamentos | |
| AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
| BR112013009827A2 (pt) | mecanismo de configuração da dose e dispositivo de distribuição do fármaco | |
| BR112013001299A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano | |
| BRPI0719523A2 (pt) | Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes | |
| HN2009003424A (es) | (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea | |
| EP2925340B8 (en) | Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods | |
| EP3318879A4 (en) | Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag | |
| ZA201101552B (en) | Composition comprising chitosan for ocular administration of vaccine(s) to avians | |
| FR2947546B1 (fr) | Derives de pyrazoles, leur preparation et leur application en therapeutique |